Pulmonx Corp. LUNG

What this company does

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). Its solution is comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the LungTraX Platform, designed to treat severe emphysema patients who are still profoundly symptomatic despite medical management and either do not want or are ineligible for surgical approaches. In 2018, Pulmonx received pre-market approval (PMA) from the U.S. Food and Drug Administration, and the Zephyr Valve is now commercially available in numerous countries globally. The company also manufactures the AeriSeal System, a synthetic polymer foam designed to occlude collateral air channels in a target lung lobe, which is not approved by the FDA or for commercial sale in the United States. It markets and sells its products in the United States through a direct sales organization, and employs both direct and distributor-based sales models internationally. For the year ended December 31, 2025, Pulmonx generated revenue of $90.5 million, with a gross margin of 74.2% and a net loss of $54.0 million, compared to revenue of $83.8 million for 2024. As of December 31, 2025, the company had a total of 296 full time employees, with 229 employees in the U.S., 56 in Europe, and 11 in Asia Pacific. Pulmonx was incorporated in the state of California on December 26, 1995 as Pulmonx and reincorporated in the state of Delaware on December 4, 2013.

Written from the business description in Pulmonx Corp's annual report to the U.S. Securities and Exchange Commission, filed 10 March 2026. Every sentence was checked against that document before publication.